Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Virax Biolabs Group (VRAX)

Annual Return

Over the past 3 years, VRAX has had an average annual return of -65.70%, underperforming the benchmark SPY, which returned +19.31% annual.

Since Jul 21, 2022, VRAX has had an average annual return of -82.68%, underperforming the benchmark SPY, which returned +18.37% annual.

20262025202420232022
-52.63%-84.68%+55%-80.05%-95.99%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026-15.79%-18.75%-7.69%-41.67%+42.86%-40.00%+50%-52.63%
2025-25.00%-1.08%-31.52%-14.29%-1.85%-16.98%+2.27%-26.67%-0%-6.06%-29.03%-13.64%-84.68%
2024-43.75%+17.78%-26.42%-10.26%+85.71%-1.54%+6.25%+276.47%-58.20%+6.54%-5.26%+14.81%+55%
2023+3.74%-10.10%+2.14%-39.79%-6.52%-0.47%+1.87%-9.63%-9.14%-24.58%-5.19%-37.50%-80.05%
2022-70.33%-34.98%-10.26%-52.05%+3.61%-53.37%-95.99%

Drawdown analysis of Virax Biolabs Group (VRAX)

The maximum drawdown for the VRAX was -99.95%, occurring on Apr 10, 2026. This drawdown has not yet recovered.

The current VRAX drawdown is -99.92%.

Since Jul 21, 2022 VRAX has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 2 times
  • 30% or more: 2 times
  • 20% or more: 2 times
  • 10% or more: 2 times
DepthStartTo BottomBottomTo RecoverEndTotal
-99.95%Jul 28, 2022928Apr 10, 2026OngoingOngoingOngoing
-43.19%Jul 21, 20221Jul 22, 20222Jul 26, 20223